The top analyst upgrades, downgrades and initiations seen on Friday morning include Advanced Micro Devices, Cliffs Natural Resources, Gap, KLA-Tencor, Regions Financial, Tyson Foods and Wal-Mart.
October 6, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Thursday’s session. On the NYSE, decliners led advancers by a slight margin…
Alnylam Pharmaceuticals saw its shares crash on Thursday after the company announced that it will be discontinuing one of its late-stage trials.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Thursday morning include American Express, Encana, Petrobras, Raytheon, Tesla and Walgreens.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, BlackBerry, eBay, Fitbit, Lululemon Athletica and Nike.
The top analyst upgrades, downgrades and initiations seen from Friday, March 11, include Blackstone, Chevron, Diamond Offshore Drilling, Palo Alto Networks, Symantec and Total.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Alnylam Pharmaceuticals and The Medicines Company made waves Monday morning despite downward pressure from the broad markets.
Chris Lange Friday's top analyst upgrades, downgrades and initiations include Alcatel-Lucent, Alibaba, CyberArk, Yelp, Rocket Fuel and Choice Hotels.
Wednesday's top analyst upgrades, downgrades and initiations includes Alcoa, Apache, Bob Evans, F5, Hain and McDonald's.
With volatility spiking much higher than last year, one thing that bodes well for equity investors is the number of insiders that continue to add to their holdings.
Thursday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls includes Alcatel-Lucent, ADM, Bank of America, Chesapeake Energy, Google, J.P. Morgan and MGM.
Friday's top analyst upgrades, downgrades and initiations include Citrix Systems, GoPro, Hewlett-Packard, Microsoft, Oracle and Teva Pharmaceutical.
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams of revenue.
ThinkstockAfter being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from the head of the Federal Reserve Janet Yellen didn’t stop the return of…
